Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.

Twilla JD, Gelfand MS, Cleveland KO, Usery JB.

J Antimicrob Chemother. 2011 Nov;66(11):2675-7. doi: 10.1093/jac/dkr329. Epub 2011 Aug 10. No abstract available.

2.

[Staphylococcus aureus and antibiotic resistance].

Sancak B.

Mikrobiyol Bul. 2011 Jul;45(3):565-76. Review. Turkish.

PMID:
21935792
3.

Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.

Yin LY, Calhoun JH, Thomas TS, Wirtz ED.

J Antimicrob Chemother. 2009 Feb;63(2):357-60. doi: 10.1093/jac/dkn490. Epub 2008 Dec 5.

4.

[Conservative treatment of a hip prosthesis infection due to methicillin-resistant Staphylococcus aureus using prolonged antibiotic therapy based on linezolid followed by daptomycin].

Grossi O, Talarmin JP, Boutoille D, Frioux R, Corvec S, Raffi F.

Med Mal Infect. 2008 Dec;38 Spec No 2:10-2. doi: 10.1016/S0399-077X(08)75153-9. French. No abstract available.

PMID:
19185203
5.

Comparative activity of telavancin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates collected from 1991 to 2006.

Shams W, Walker ES, Levy F, Reynolds SA, Peterson SM, Sarubbi FA.

Chemotherapy. 2010;56(5):411-6. doi: 10.1159/000318057. Epub 2010 Oct 15.

PMID:
20948212
6.

Comment on: Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure.

Cleveland KO, Memon KA.

J Antimicrob Chemother. 2011 Dec;66(12):2891; author reply 2891-2. doi: 10.1093/jac/dkr369. Epub 2011 Sep 7. No abstract available.

7.

Comment on: Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure.

Camou F.

J Antimicrob Chemother. 2012 Feb;67(2):514; author reply 515. doi: 10.1093/jac/dkr469. Epub 2011 Nov 11. No abstract available.

8.

Methicillin-resistant Staphylococcus aureus: the superbug.

Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP.

Int J Infect Dis. 2010 Oct;14 Suppl 4:S7-11. doi: 10.1016/j.ijid.2010.05.003. Epub 2010 Sep 20. Review.

9.

Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure.

Joson J, Grover C, Downer C, Pujar T, Heidari A.

J Antimicrob Chemother. 2011 Sep;66(9):2186-8. doi: 10.1093/jac/dkr234. Epub 2011 Jun 8. No abstract available.

10.

In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.

Mendes RE, Moet GJ, Janechek MJ, Jones RN.

Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.

11.

Treatment of methicillin-resistant Staphylococcus aureus surgical site infections.

Santayana EM, Jourjy J.

AACN Adv Crit Care. 2011 Jan-Mar;22(1):5-12; quiz 14. doi: 10.1097/NCI.0b013e3181ef86fe2049019. Review. No abstract available.

PMID:
21297385
12.

Drugs for MRSA with reduced susceptibility to vancomycin.

[No authors listed]

Med Lett Drugs Ther. 2009 May 4;51(1311):36; quiz 37. No abstract available.

PMID:
19417720
13.

Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.

Nannini E, Murray BE, Arias CA.

Curr Opin Pharmacol. 2010 Oct;10(5):516-21. doi: 10.1016/j.coph.2010.06.006. Epub 2010 Jul 1. Review.

PMID:
20598637
14.

Antimicrobial agents in treatment of MRSA infections.

Johnson MD, Decker CF.

Dis Mon. 2008 Dec;54(12):793-800. doi: 10.1016/j.disamonth.2008.09.002. Review. No abstract available.

PMID:
18996282
15.

Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.

Loffler CA, Macdougall C.

Expert Rev Anti Infect Ther. 2007 Dec;5(6):961-81.

PMID:
18039081
16.

In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.

Kao TM, Wang JT, Weng CM, Chen YC, Chang SC.

J Microbiol Immunol Infect. 2011 Oct;44(5):346-51. doi: 10.1016/j.jmii.2011.01.037. Epub 2011 Jan 20.

17.

Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.

Campbell ML, Marchaim D, Pogue JM, Sunkara B, Bheemreddy S, Bathina P, Pulluru H, Chugh N, Wilson MN, Moshos J, Ku K, Hayakawa K, Martin ET, Lephart PR, Rybak MJ, Kaye KS.

Ann Pharmacother. 2012 Dec;46(12):1587-97. doi: 10.1345/aph.1R211. Epub 2012 Dec 4.

PMID:
23212935
18.

Treatment of infections caused by resistant Staphylococcus aureus.

Anstead GM, Quinones-Nazario G, Lewis JS 2nd.

Methods Mol Biol. 2007;391:227-58. Review.

PMID:
18025681
19.

Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.

Gould IM.

J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21. doi: 10.1093/jac/dkr073. Review.

20.

Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia.

Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO.

Diagn Microbiol Infect Dis. 2011 Nov;71(3):286-90. doi: 10.1016/j.diagmicrobio.2011.07.001. Epub 2011 Aug 19.

PMID:
21855248
Items per page

Supplemental Content

Write to the Help Desk